Posaconazole Pharmacokinetics in Patients Receiving Chemotherapy or Stem Cell Transplants

ConditionsPosaconazole Pharmacokinetics Invasive Candidiases Invasive Aspergillosis Invasive Mycosis Fungal Infection Prophylaxis

Trial statusRecruiting

Trial phasePhase 4

Trial typeInterventional

Biological sexAll

Age18+

SponsorMelbourne Health

About this trial

The purpose of the study is to investigate the pharmacokinetics of oral dosage of Posaconazole which is routinely administered as a standard care prophylaxis for patients undergoing cancer treatments.

Eligibility criteria

Qualifiers

Adult (≥18 years old) haematology patients receiving Posaconazole prophylaxis in the inpatient setting as standard of care.

Able to give informed consent.

Disqualifiers

Unable to give informed consent.

Trial design

Treatments tested in this trial

Posaconazole pharmacokinetics

Treatment groups

100 Participants

are divided into 1 treatment group

Sponsors and collaborators

Melbourne Health

Lead sponsor

Merck Sharp & Dohme LLC

Collaborator

Source ClinicalTrials.gov